Phenobarbital treatment efficacy study

Clinical Score: 0.900 Price: $0.50 intractable epilepsy human patient and Gabra1+/-/Gabrg2+/- mice Status: proposed

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting GABRA1, GABRG2 in human patient and Gabra1+/-/Gabrg2+/- mice. Primary outcome: seizure control

Description

Treatment study evaluating the efficacy of phenobarbital as an anticonvulsant in both the mouse model and human patient. After multiple anti-seizure drugs failed in the patient, phenobarbital was found to be the most effective treatment for seizure control. This finding was validated in the mouse model, demonstrating translational relevance and providing therapeutic guidance for similar cases.

TARGET GENE
GABRA1, GABRG2
MODEL SYSTEM
human patient and Gabra1+/-/Gabrg2+/- mice
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
GABAergic neurotransmission
SOURCE
extracted_from_pmid_37703949
PRIMARY OUTCOME
seizure control

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

GABRA1 GenegeneGABRG2 — GABA-A Receptor Gamma2 SubunitgeneGABRA1 ProteinproteinGABRG2 Protein — GABA-A Receptor Gamma2 SubunitproteinEpilepsydisease

Protocol

phenobarbital treatment with EEG monitoring

Expected Outcomes

effective seizure control with phenobarbital

Success Criteria

seizure reduction/control

Related Hypotheses (1)

Biorhythmic Interference via Controlled Sleep Oscillations0.661

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.